References
- Fujii S, Fukushima M, Shimamoto Y, Ohshimo H, Imaoka T, Shirasaka T. Antitumor activity of BOF-A2, a new 5-fluoro-uracil derivative. Jpn J Cancer Res 1989; 80: 173–81
- Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748–55
- Fujii S, Shimamoto Y, Ohshimo H, et al. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibition of 5-fluorouracil degradation on Yoshida sarcomas in rats. Jpn J Cancer Res 1989; 80: 167–72
- Shirasaka T, Fukushima M, Shimamoto Y, et al. Metabolic characteristics and antitumor activity of BOF-A2, a new 5-flourouracil derivative. Jpn J Cancer Chemother 1990; 17: 1051–8
- Shirasaka T, Fujita F, Fujita M, Fukushima M, Taguchi T, Fujii S. Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancer xeno-grafted in nude mice. Jpn J Cancer Chemother 1990; 17: 1871–6
- Suzuoki Y, Saito T, Taguchi T, et al. Phase I clinical study of BOF-A2, a new 5-fluorouracil derivative. Proceedings of the 49 th annual meeting of Japanese Cancer Association Sapporo, Japan, 1990; 49
- Hasegawa K, Taguchi T, Niitani H, Furue H, Kimura K. Early phase II trial of BOF-A2, a new 5-FU derivative. J Jpn Soc Cancer Ther 1990; 25: 235
- Furue H, Hara Y, Imai Y, et al. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993; 28: 101–30
- WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. World Health Organization, Geneva 1979
- Weiden P L, Einstein A B, Rudolph R H. Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. Cancer Treat Rep 1985; 69: 1253–5
- Richards F, Perry D, Goutsou M, et al. Chemotherapy with 5-fluorouracil [5-FU] and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the Cancer and Leukemia Group B. Cancer 1991; 67: 2974–9
- Valdivieso M, Bodey G P, Gottlieb J A, Freileich E. Clinical evaluation of ftorafur (pyrimidine-deoxyribose N,-2′-furanidyl-5-fluorouracil). Cancer Res 1976; 36: 1821–4
- Ansfield F J, Kallas G J, Singson J P. Phase I-II studies of oral tegafur (Ftorafur). J Clin Oncol 1983; 1: 107–11
- Keicho N, Saijo N, Shinkai T, et al. Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 1986; 16: 143–6
- Hara Y. 5′-deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues. Jpn J Cancer Chemother 1984; 11: 2133–43
- Niitani H, Kimura K, Saito T, et al. Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer-Multi-institutional cooperative study. Jpn J Cancer Chemother 1985; 12: 2044–51
- Ettinger D S. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991; 7: 113–22
- Matsui Y, Izumi T, Niitani H. Concentrations of 5-FU in the blood, normal lung tissues and lung cancer tissues after oral administration of BOF-A2 and UFT in lung cancer patients. Abstracts of 18th International Congress of Chemotherapy, 1993 Jun 27-July 2, StockholmSweden
- Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothesin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16–20